CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: The identification of the over-expression of these CSC-specific markers in the CD34+/CD38− CML cells, has been associated with tumor aggressiveness, metastasis, resistance to treatment and tumor recurrence [1, 3], thus defining an enhanced hCSC-like phenotype.